Tag Archives: AIMT

Top 10 Value Stocks For 2019

Shares of Government Properties Income Trust (NASDAQ:GOV) have been given an average rating of “Hold” by the eleven analysts that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.40.

GOV has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Government Properties Income Trust from a “sell” rating to a “hold” rating in a report on Tuesday, June 5th. BidaskClub raised shares of Government Properties Income Trust from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Royal Bank of Canada set a $14.00 price target on shares of Government Properties Income Trust and gave the company a “sell” rating in a report on Wednesday, August 8th. TheStreet raised shares of Government Properties Income Trust from a “d+” rating to a “c” rating in a report on Friday, August 3rd. Finally, ValuEngine lowered shares of Government Properties Income Trust from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd.

Top 10 Value Stocks For 2019: California Grapes International, Inc. (CAGR)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    It is hard to fully wrap your hands around the potential market opportunity that Accenture will have in the years ahead but I believe that the opportunities are almost endless (dramatic, I know). For example, consider these forecasts that Forbes detailed in its “2017 Roundup Of Internet Of Things Forecast” report:

    According to Bain, “B2B IoT segments will generate more than $300B annually by 2020, including about $85B in the industrial sector”. According to PwC, “$6T will be spent on IoT solutions between 2015 and 2020”. According to Accenture, “Industrial Internet Of Things could add $14.2T to the economy by 2020”. According to Statista, “The global Internet of Things (IoT) market is projected to grow from $2.99T in 2014 to $8.9T in 2020, attaining a 19.92% Compound Annual Growth Rate (OTCPK:CAGR). Industrial manufacturing is predicted to increase from $472B in 2014 to $890B in global IoT spending. Healthcare and life sciences are projected to increase from $520B in 2014 to $1.335T in 2020, attaining a 17% CAGR”.

    The forecasts compiled by Forbes are all over the place but one thing is consistent, that is, the growth potential for IoT (and the sub-industries) is real. Connected things are expected to experience significant growth and I believe that it is hard to deny that digital will play a key role in the future growth of the global economy.

Top 10 Value Stocks For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) will present data on its Phase 3 study of AR101 for the treatment of peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology annual meeting, taking place February 22 to 25 in San Francisco. Specifically, this data will come out on the morning of February 24.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

Top 10 Value Stocks For 2019: Chesapeake Energy Corporation(CHK)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Chesapeake Energy (CHK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Paul Ausick]

    Chesapeake Energy Corp. (NYSE: CHK) traded down about 0.3% at $4.74 in a 52-week range of $2.53 to $5.20.

    EOG Resources Inc. (NYSE: EOG) traded flat at $118.05. The 52-week range is $81.99 to $128.03.

  • [By Paul Ausick]

    Here’s how share prices of the largest U.S. natural gas producers reacted to today’s report:

    Exxon Mobil Corp. (NYSE: XOM), the country’s largest producer of natural gas, traded down about 2.4%, at $80.21 in a 52-week range of $72.16 to $89.30. Chesapeake Energy Corp. (NYSE: CHK) traded down about 1.8%, at $4.55 in a 52-week range of $2.53 to $5.68. EOG Resources Inc. (NYSE: EOG) traded down about 2.1% to $120.38. The 52-week range is $81.99 to $128.03.

    Also, the United States Natural Gas ETF (NYSEARCA: UNG) traded up about 0.3%, at $23.99 in a 52-week range of $20.40 to $29.96.

  • [By Paul Ausick]

    Here’s how share prices of the largest U.S. natural gas producers reacted to this latest report:

    Exxon Mobil Corp. (NYSE: XOM), the country’s largest producer of natural gas, traded up about 1.3%, at $80.98 in a 52-week range of $72.16 to $89.30. Chesapeake Energy Corp. (NYSE: CHK) traded up about 2.0% to $3.33, in a 52-week range of $2.86 to $3.34. EOG Resources Inc. (NYSE: EOG) traded up about 1% to $118.92. The 52-week range is $81.99 to $119.71.

    The United States Natural Gas ETF (NYSEARCA: UNG) traded up about 2.4%, at $22.83 in a 52-week range of $20.40 to $31.72.

Top 10 Value Stocks For 2019: Urban Outfitters Inc.(URBN)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    Click here now.

    Stocks to Watch Today: TGT, CRM, FB
    This morning, shares of Target Corp. (NYSE: TGT) popped nearly 6% after a strong Q4 earnings report. The company reported earnings per share of $1.53 on total revenue of $22.98 billion. Wall Street expected $1.52 per share on sales of $22.91 billion. The firm reported very strong online sales (up 25%) and a 5.3% jump in same-store sales. Analysts had expected a 4.5% increase in same-store sales. The report is the latest sign that Target has emerged as a formidable competitor to Amazon.com Inc. (NASDAQ: AMZN) and Walmart Inc. (NYSE: WMT). Facebook Inc. (NASDAQ: FB) is under fire again due to security concerns around its sign-in features. The company has not allowed users to opt out of the key feature that lets users look up others by phone number and e-mail address. Many people have added their phone numbers in the past thinking it would only be used for two-factor authentication and security. Critics argue this is the latest episode of Facebook compromising user information. Shares of Salesforce.com Inc. (NYSE: CRM) are in focus as the cloud computing giant plans to report earnings after the bell Tuesday. CRM stock is already up 20% so far this year. And many analysts expect the firm to report earnings per share of $0.55 on top of $3.56 billion in revenue. Yesterday, Salesforce co-CEO Marc Benioff predicted that $30 billion in annual revenue for the cloud computing giant is “right around the corner.” Look for earnings reports from AeroVironment Inc. (NASDAQ: AVAV), Ambarella Inc. (NASDAQ: AMBA), Ciena Corp. (NASDAQ: CIEN), Kohl’s Corp. (NYSE: KSS), Ross Stores Inc. (NASDAQ: ROST), Sina Corp. (NASDAQ: SINA), Urban Outfitters Inc. (NASDAQ: URBN), Vivint Solar Inc. (NASDAQ: VSLR), and Weibo Corp. (NYSE: WB).

    Follow Money Morning on Facebook, Twitter, and LinkedIn.

  • [By Timothy Green]

    Shares of apparel retailer Urban Outfitters (NASDAQ:URBN) sank on Wednesday despite a monthly retail sales report from the U.S. Census Bureau showing solid growth in July clothing sales. An analyst downgrade on Tuesday and a disappointing quarterly report from Macy’s (NYSE:M) could be weighing on the stock. Shares of Urban Outfitters were down about 5.4% at 12:10 p.m. EDT.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Urban Outfitters (URBN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks For 2019: SandRidge Mississippian Trust II(SDR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Matador Resources (NYSE: MTDR) and SandRidge Mississippian Trust II (NYSE:SDR) are both oils/energy companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

  • [By Logan Wallace]

    Shares of SCHRODERS/PAR VTG FPD 1 (LON:SDR) have earned a consensus recommendation of “Hold” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is GBX 3,576.11 ($46.73).

Top 10 Value Stocks For 2019: LightInTheBox Holding Co., Ltd.(LITB)

Advisors’ Opinion:

  • [By Logan Wallace]

    News stories about Lightinthebox (NYSE:LITB) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lightinthebox earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 46.3507616645709 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Top 10 Value Stocks For 2019: Golfsmith International Holdings Inc.(GOLF)

Advisors’ Opinion:

  • [By Shane Hupp]

    DA Davidson reissued their hold rating on shares of Acushnet (NYSE:GOLF) in a research note published on Monday.

    A number of other research analysts have also issued reports on the stock. Morgan Stanley reiterated an overweight rating on shares of Acushnet in a report on Thursday, March 8th. ValuEngine upgraded shares of Acushnet from a hold rating to a buy rating in a report on Thursday, February 8th. SunTrust Banks reiterated a buy rating and issued a $26.00 price objective on shares of Acushnet in a report on Wednesday, April 11th. Compass Point lowered shares of Acushnet from a buy rating to a neutral rating and set a $24.00 price objective for the company. in a report on Monday, March 19th. Finally, KeyCorp reiterated an overweight rating on shares of Acushnet in a report on Thursday, March 8th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $23.40.

  • [By Joseph Griffin]

    Golfcoin (CURRENCY:GOLF) traded down 11.2% against the dollar during the 24-hour period ending at 10:00 AM E.T. on October 4th. Over the last week, Golfcoin has traded down 59.6% against the dollar. One Golfcoin coin can now be bought for about $0.0001 or 0.00000001 BTC on popular cryptocurrency exchanges. Golfcoin has a market capitalization of $114,793.00 and $48.00 worth of Golfcoin was traded on exchanges in the last 24 hours.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Golfsmith International (GOLF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks For 2019: Identiv, Inc.(INVE)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results.
    MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results.
    ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million.
    Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results.
    Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results.
    VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71.
    Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results.
    Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results.
    Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739.
    Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69

Top 10 Value Stocks For 2019: Kingstone Companies, Inc(KINS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Kingstone Companies (KINS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    RLI (NASDAQ: KINS) and Kingstone Companies (NASDAQ:KINS) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

  • [By Stephan Byrd]

    Kingstone Companies (NASDAQ:KINS) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

    Kosmos Energy (NYSE:KOS) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

  • [By Joseph Griffin]

    AXIS Capital (NYSE: AXS) and Kingstone Companies (NASDAQ:KINS) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Kingstone Companies (KINS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks For 2019: United Dominion Realty Trust, Inc.(UDR)

Advisors’ Opinion:

  • [By Shane Hupp]

    UDR, Inc. (NYSE:UDR) SVP Harry G. Alcock sold 10,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $40.45, for a total value of $404,500.00. Following the transaction, the senior vice president now owns 126,123 shares of the company’s stock, valued at $5,101,675.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on UDR (UDR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    News articles about United Dominion Realty Trust (NYSE:UDR) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. United Dominion Realty Trust earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the real estate investment trust an impact score of 47.5630416063411 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Best Safest Stocks For 2019

Things aren’t going to script right now in the financial sector. It’s a widely established fact (based on years of historical evidence) that banks and other lenders typically prosper when interest rates are rising. In previous rate-tightening cycles, the financial sector was usually among the market’s top performers.

—Recommended Link— Create A 10%+ Income Stream For Life
We’re sitting on a collection of the safest, most generous monthly payers available. And while $11,200 in dividend checks is a welcome addition to anyone’s income, investors also love racking up capital gains as high as 446%. Start generating a 10%+ income stream for life today from these consistent companies.

As I’ve discussed before in my High-Yield Investing premium newsletter, banks can feast in these conditions because the rates they charge borrowers on loans usually rise faster than the rates they pay to depositors. That widens net interest margins (NIMs) and fattens the bottom line.

Best Safest Stocks For 2019: NIC Inc.(EGOV)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of NIC (NASDAQ:EGOV) from a buy rating to a strong-buy rating in a research note published on Friday morning.

    Several other research firms also recently commented on EGOV. Zacks Investment Research downgraded NIC from a hold rating to a sell rating in a report on Monday, January 8th. ValuEngine downgraded NIC from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Barrington Research restated a hold rating on shares of NIC in a report on Monday, April 30th. TheStreet downgraded NIC from a b- rating to a c rating in a report on Thursday, March 8th. Finally, Loop Capital decreased their price objective on NIC to $14.00 and set a hold rating for the company in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $18.33.

  • [By Max Byerly]

    Shares of NIC Inc. (NASDAQ:EGOV) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $18.00.

  • [By Joseph Griffin]

    Media headlines about NIC (NASDAQ:EGOV) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NIC earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the software maker an impact score of 44.2220263592641 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Joseph Griffin]

    NIC Inc. (NASDAQ:EGOV) has been given a consensus recommendation of “Hold” by the ten research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

Best Safest Stocks For 2019: Western Asset Mortgage Capital Corporation(WMC)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine lowered shares of Western Asset Mortgage Capit (NYSE:WMC) from a buy rating to a hold rating in a research report report published on Wednesday.

Best Safest Stocks For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed most recently at $36.18, with a consensus price target of $57.38 and a 52-week range of $15.97 to $40.65.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

Best Safest Stocks For 2019: Infinity Pharmaceuticals, Inc.(INFI)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine upgraded shares of Infinity Pharmaceuticals (NASDAQ:INFI) from a sell rating to a hold rating in a report published on Saturday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.

Best Safest Stocks For 2019: Royal Dutch Shell PLC(RDS.A)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    Much of Wall Street will tell you to stick with the oil industry giants – companies like Exxon Mobil Corp. (NYSE: XOM) or Royal Dutch Shell Plc. (NYSE: RDS.A).

Top Low Price Stocks To Own For 2019

Private equity shops thought they saw a sure-fire way to make a buck: build dozens of new power plants fueled by cheap Appalachian natural gas to replace old coal-fired units.

It hasn’t quite turned out that way, at least not yet. Many of the new plants built in the last few years aren’t kicking off as much cash as the buyout firms had expected, according to bankers. There’s not enough demand to support the huge amount of additional new capacity, driving down electricity prices. And with President Donald Trump as a booster, shutdowns of coal haven’t come as quickly as anticipated while states are acting to keep nuclear plants open.

None of the new plants appear in danger of default, analysts said. But several plant owners are now using most of the extra cash they are generating to pay down debt.

Moreover, low prices and the results of a closely watched regional power-price auction scheduled for Wednesday could force many of the gas-fired plants built in the last five years to refinance their debt. At least one new U.S. plant, owned in part by an arm of private equity firm Ares Management LP, recently did so.

Top Low Price Stocks To Own For 2019: DigitalGlobe, Inc(DGI)

Advisors’ Opinion:

Top Low Price Stocks To Own For 2019: Patterson-UTI Energy, Inc.(PTEN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Thrivent Financial for Lutherans increased its stake in Patterson-UTI (NASDAQ:PTEN) by 31.8% during the 1st quarter, Holdings Channel reports. The firm owned 3,073,057 shares of the oil and gas company’s stock after purchasing an additional 741,573 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Patterson-UTI were worth $53,810,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Patterson-UTI Energy (PTEN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    First Pacific Advisors LLC decreased its holdings in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) by 15.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,451,909 shares of the oil and gas company’s stock after selling 273,567 shares during the quarter. First Pacific Advisors LLC owned 0.65% of Patterson-UTI Energy worth $25,423,000 at the end of the most recent reporting period.

Top Low Price Stocks To Own For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

Best Blue Chip Stocks To Buy Right Now

Shutterstock

Today I’m going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too.

I’ll also reveal a blue chip stock that’s delivering both strong price gains and rising dividends. It will have you pocketing a nice 5%+ yield in short order.

So let’s get going, starting with…

The Dividend-Growth Signal Most People Miss

If you’ve been buying dividend stocks for a while, you probably know about the payout ratio.

It’s a sacred cow for many folks; you calculate it by dividing the total amount of dividends paid by the company’s last 12 months of net income.

If it comes out in the neighborhood of, say, 50% or less, you’ve got a safe dividend that’s likely to grow. As you get climb closer to 100%, the noose around the payout gets tighter.

Best Blue Chip Stocks To Buy Right Now: Skyworks Solutions, Inc.(SWKS)

Advisors’ Opinion:

  • [By ]

    We’ve bagged winners like the 64.3% return from Mastercard (NYSE: MA), 44.3% from Intel (Nasdaq: INTC), 38.9% from Deere (NYSE: DE) and even 101.8% from Skyworks Solutions (Nasdaq: SWKS). So it’s easy to see why this has become one of StreetAuthority’s most popular reports.

  • [By Harsh Chauhan]

    More importantly, Apple could build around 120 million new iPhones this year as compared to 89 million units of the iPhone 7/7S in 2016 — according to Mizuho. This is great news for the other companies in Cupertino’s supply chain — such as Skyworks Solutions (NASDAQ:SWKS), Broadcom (NASDAQ:AVGO), and Cypress Semiconductor (NASDAQ:CY) — as they won’t have to wait until the second half of the year to bask in iPhone-driven glory.

  • [By WWW.THESTREET.COM]

    But Skyworks  (SWKS) reported a remarkable quarter, yet it’s getting hit.

    It showed some terrific Internet of Things orders and not just Apple  (AAPL) and Samsung, although both are excellent customers in a very big year.

  • [By Ben Levisohn]

    Skyworks Solutions (SWKS) soared to the top of the S&P 500 today after beating first-quarter earnings forecasts, and offering above-consensus second-quarter guidance.

    Getty Images

    Skyworks Solutions gained 13% to $88.67, while the S&P 500 rose 0.3% to 2,271.31.

    Oppenheimer’s Rick Schafer and team argue that Skyworks’ “growth [is] back on track.” They explain:

    We expect Skyworks to deliver above-market growth driven by 1) continued smartphone content gains; 2) China share gains through strengthening baseband partnerships and demand for integrated (vs. discrete) RF solutions; 3) seasonal uptick at Samsung; and 4) continued double-digit RF complexity increases. With its “one-stop-shop” systems-level approach, we seeSkyworks uniquely positioned to benefit from rising RF content. We reiterate Outperform and raise PT to $105 from $100.

    Skyworks Solutions’ market capitalization rose to $16.5 billion today from $14.6 billion yesterday.

  • [By Benzinga News Desk]

    Former President George H.W. Bush has been hospitalized in Houston with an infection, just after attending the funeral of his wife, Barbara, a spokesman said Monday: Link

    ECONOMIC DATA
    Redbook Reports US Retail Sales During First 2 Weeks Of Apr. Up 0.3% MoM, Up 2.8% YoY
    USA S&P/CaseShiller House Price Index (MoM) for Feb Up 0.7% MoM
    New home sales report for March will be released at 10:00 a.m. ET.
    The Conference Board’s consumer sentiment index for April is schedule for release at 10:00 a.m. ET.
    The Richmond Fed manufacturing index for April will be released at 10:00 a.m. ET.
    The Treasury is set to auction 4-and 52-week bills at 11:30 a.m. ET.
    The Treasury will auction 2-year notes at 1:00 p.m. ET.
    ANALYST RATINGS
    Leerink upgraded Cardinal Health (NYSE: CAH) from Market Perform to Outperform
    Berenberg upgraded Emerson Electric (NYSE: EMR) from Sell to Hold
    Mizuho downgraded Skyworks (NASDAQ: SWKS) from Buy to Neutral
    BMO downgraded Texas Roadhouse (NASDAQ: TXRH) from Outperform to Market Perform

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Rich Smith]

    Is that good news or bad news for Apple? According to a different analyst today, the answer to that question is beside the point: The one thing Mizuho Securities is sure of is that this is bad news for Skyworks Solutions (NASDAQ:SWKS).

Best Blue Chip Stocks To Buy Right Now: Regions Financial Corporation(RF)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Regions Financial (RF) , Edwards Lifesciences (EW) , Qualys (QLYS) and HEICO (HEI) .

  • [By ]

    Regions Financial (NYSE: RF) could be a beneficiary of the move to deregulation in banking this year and is expected to grow earnings by 24% to $1.35 per share. The bank is seeing strong growth in non-interest income sources and management has a plan to cut up to 10% in operating expenses for greater profitability. Regions has a strong deposit base across the Southeast and averages a 7% return on equity, well above the industry average.

  • [By ]

    Regions Financial (RF) : “I think this one is real good. I like the banks here.”

    Edwards Lifesciences (EW) : “They have the best devices. That stock is a buy.”

  • [By Sean Williams]

    Income investors often turn to bank stocks when looking for a steady dividend, but few offer the dividend growth potential of Southeastern regional bankRegions Financial (NYSE:RF).

Best Blue Chip Stocks To Buy Right Now: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By ]

    Aimmune Therapeutics (AIMT) : “I do like it. That’s an important niche business. “

    Ingersoll-Rand (IR) : “I like Ingersoll-Rand. They work well at this phase in the cycle.”

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Best Blue Chip Stocks To Buy Right Now: Washington Trust Bancorp, Inc.(WASH)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Best Blue Chip Stocks To Buy Right Now: Washington Federal, Inc.(WAFD)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    The six companies that met the criterion are:

    Oshkosh Corp (NYSE: OSK). Phillips 66 (NYSE: PSX). SpartanNash Co (NASDAQ: SPTN). Suncor Energy Inc. (USA) (NYSE: SU). Washington Federal Inc. (NASDAQ: WAFD). Barnes & Noble, Inc. (NYSE: BKS).
    Oshkosh

    Oshkosh is a manufacturer of specialty vehicles and vehicle bodies and is based in Wisconsin. The company operates under four business segments, namely access equipment, defense, fire and emergency, and commercial.

Best Blue Chip Stocks To Buy Right Now: Quidel Corporation(QDEL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Quidel Corporation (NASDAQ: QDEL) shares were also up, gaining 8 percent to $44.31. Piper Jaffray upgraded Quidel from Neutral to Overweight.

    Equities Trading DOWN

Top 5 Bank Stocks For 2018

Eldorado Resorts (NASDAQ:ERI) has been given a consensus rating of “Buy” by the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $41.56.

A number of equities research analysts have commented on ERI shares. Jefferies Group started coverage on Eldorado Resorts in a report on Thursday, January 18th. They issued a “buy” rating and a $40.00 target price for the company. BidaskClub downgraded Eldorado Resorts from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Zacks Investment Research downgraded Eldorado Resorts from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 20th. Roth Capital started coverage on Eldorado Resorts in a report on Tuesday, February 20th. They issued a “buy” rating and a $41.00 target price for the company. Finally, SunTrust Banks reissued an “average” rating and issued a $36.00 target price on shares of Eldorado Resorts in a report on Monday, February 5th.

Top 5 Bank Stocks For 2018: Henry Schein, Inc.(HSIC)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Henry Schein, Inc. (NASDAQ: HSIC) which rose over 6% to $73.68. The stocks 52-week range is $62.56 to $93.50. Volume was 3.3 million compared to the daily average volume of 1.9 million.

Top 5 Bank Stocks For 2018: Sharp Corp (SHCAF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The company is partnering with Chinese company OXi Technology (in which it also made a strategic investment) for developing fingerprint sensor under glass and in the bezel of smartphones. Its fingerprint sensor business received a boost from the Samsung (OTC:SSNLF) S8 and S8+ design wins (as well as Sharp’s (OTCPK:SHCAF) Aquos R and ZTE ZMax Pro).

Top 5 Bank Stocks For 2018: Williams Partners L.P.(WPZ)

Advisors’ Opinion:

  • [By Ben Levisohn]

    In a release after the close on Monday, Williams and Williams Partners (WPZ) made several announcements, including: 1) outlining managements plan to financially reposition and simplify the franchises GP/LP structure in an ~$11.4 billion transaction (not subject to any additional approvals), 2) adjustments to Williams and Williams Partners’ dividend and distribution payouts, 3) initiating a ~$2+ billion William equity raise to fund a further Williams investment in Williams Partners, 4) noted other potential upcoming changes, including the sale of ~$2 billion in non-core assets in 2017, and 5) provided several forms of updated 2017 guidance…

Top 5 Bank Stocks For 2018: EV Energy Partners, L.P.(EVEP)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
    My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
    DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
    CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
    China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
    Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
    Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
    Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
    Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
    EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

  • [By William Romov]

    Before we show you our pick, here are the top 10 penny stocks to watch this week

    Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
    Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
    Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
    Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
    UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
    WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
    PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
    EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
    Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free

Top 5 Bank Stocks For 2018: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Shares of Aimmune Therapeutics Inc (NASDAQ: AIMT) got a boost, shooting up 35 percent to $34.73 in response to failed DBVT peanut allergy trial.

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Jim Robertson]

    Small cap clinical-stage biopharmaceutical stock Aimmune Therapeutics (NASDAQ: AIMT) is aclinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune Therapeutics first investigational biologic product using CODIT⒙is AR101 for the treatment of peanut allergy.AR101 has received the FDAs Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials where enrollment was announced last month.